Drug Database
IN

inactivated whole virion H1N1 vaccine (Enzavac)

✓ Approved

Serum Institute of India Pvt. Ltd. · 疫苗 · 疫苗

什么是 inactivated whole virion H1N1 vaccine?

inactivated whole virion H1N1 vaccine 是一种疫苗,由Serum Institute of India Pvt. Ltd.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名Enzavac
公司Serum Institute of India Pvt. Ltd.
药物类别疫苗, 大分子
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved

相关研究文献

PubMedInfluenza and other respiratory viruses2026-11-17

A Canadian Laboratory-Based Retrospective of the 2024/2025 Influenza Season: Monitoring the Impacts of Influenza Evolution on Viral Antigenicity and Antiviral Susceptibility.

Ranadheera Charlene C, Gao Ruimin R, Buchanan Cody C, Frost Jasmine J et al.

Seasonal influenza affects thousands of Canadians each year and places significant strain on workplaces and the health systems. Robust laboratory-based surveillance is essential to monitor viral evolution and evaluate the suitability of medical countermeasures. The Canadian Influenza Surveillance Program characterizes circulating influenza viruses to determine genetic clades, monitor evolutionary trends, assess antigenicity and vaccine strain relatedness, and evaluate susceptibility to neuraminidase inhibitors. Methods include whole genome sequencing, hemagglutination inhibition assays, and neuraminidase inhibition assays. From September 1, 2024 to August 31, 2025, the program antigenically characterized 1563 influenza isolates identified and submitted by Canadian laboratories. Of these, 99.4% of influenza A/H1N1, 86.6% of influenza A/H3N2, and 100% of influenza B isolates were antigenically related to their respective component of the 2024-2025 Northern Hemisphere vaccine. Genetic analysis of influenza A/H3N2 isolates identified three distinct mutation clustering patterns associated with reduced antigenic reactivity to the vaccine strain. Additionally, 1567 influenza viruses underwent antiviral susceptibility testing. Eleven influenza A/H1N1 isolates showed reduced inhibition to oseltamivir and two to zanamivir, all containing known resistance-associated markers. These findings highlight the importance of comprehensive virological assessment, integrating genotypic and phenotypic data, to inform annual vaccine strain selection and support clinical decision-making.

PMID 43039871
阅读全文 →
PubMedFrontiers in veterinary science2026-11-17

Ginsenoside Rg1 as an adjuvant enhances immunity in chickens immunized with the H9N2 avian influenza inactivated vaccine.

Zhang Pengju P, Wang Hongtao H, Li Mengman M, Lyu Xuefeng X et al.

To investigate the potential use of Ginsenoside Rg1 as an adjuvant for the H9N2 avian influenza vaccine, the study examined Rg1's immunomodulatory effects on an inactivated H9N2 vaccine. A total of 150 one-day-old non-immunized Arbor Acres (AA) chickens were randomly assigned to three groups (n = 50 each): one receiving the H9N2 inactivated vaccine, another receiving Rg1 alongside the vaccine, and a control group treated with PBS. Each group underwent three immunization sessions spaced 2 weeks apart. Serum samples were taken to measure IgG antibody levels and hemagglutination inhibition (HI) titers. Lymphocyte proliferation was assessed using cell counting kits-8 and flow cytometry. The levels of serum cytokines, including Interferon-γ (IFN-γ), tumor necrosis factor-alpha (TNF-α), interleukin (IL)-4, and IL-6, were quantified via ELISA. Fourteen days post-final immunization, the chickens were challenged with the H9N2 strain, and viral titers in the lungs and kidneys were measured. Findings indicated that the group receiving Rg1 with the vaccine exhibited a notable increase in specific IgG and HI titers. Furthermore, this group showed enhanced T cell proliferation and elevated cytokine production, thereby bolstering cellular immunity. Importantly, the immune protection results revealed that the combination of Rg1 and the vaccine significantly improved the chickens' protection against viral strains, leading to a marked reduction in viral shedding. These findings imply that Rg1 may enhance the immune response and protective efficacy of the H9N2 inactivated vaccine, positioning it as a promising new adjuvant for H9N2 vaccination.

PMID 43041234
阅读全文 →
PubMedThe Journal of infectious diseases2026-11-17

A prospective, comparative cohort analysis of influenza antibody waning in Michigan and Hong Kong during periods of low influenza circulation.

Yang Yanyupei Y, Smith Matthew M, Ho Faith F, Truscon Rachel R et al.

Reduced influenza transmission during the COVID-19 pandemic prompted concern about waning of population immunity that could lead to subsequent surges in circulation. We compared longitudinal influenza antibody titers in Michigan and Hong Kong, two regions with reduced influenza transmission during the COVID-19 pandemic. In two prospective cohort studies (HIVE, Michigan; EPI-HK, Hong Kong), we analyzed longitudinal serum samples collected from 2020 through 2023 from participants without influenza infection or vaccination. Sera were tested using hemagglutination inhibition assays (HAI) and microneutralization (MN) against vaccine strains. Two-year fold changes in titers were estimated using multivariable power-law models adjusted for age and baseline titer. We analyzed 173 sera from 57 HIVE participants and 259 sera from 60 EPI-HK participants. Initial HAI geometric mean titers ranged from 12.3-123.4 in HIVE and 6.3-40.9 in EPI-HK. Among those with >1:40 baseline titers in HIVE, fold-change estimates indicated waning for H1N1 strains, including A/Brisbane (0.70 [95% CI: 0.56,0.86]), A/Idaho (0.40 [0.32,0.50]), and A/Michigan (0.43 [0.34,0.52]), while H3N2 and influenza B showed minimal or no waning. In EPI-HK, fold-change estimates demonstrated heterogeneous patterns by strain for H1N1, and waning for selected H3N2 strains, including A/Cambodia (0.44 [0.29,0.65]) and A/Singapore (0.48 [0.33,0.69]). MN results were consistent with HAI findings. Influenza antibody responses during the pandemic showed heterogeneous, strain-specific changes rather than uniform decline. These findings suggest that population immunity was maintained for many strains despite reduced viral circulation, with waning occurring in particular strains and varying by population.

PMID 43043347
阅读全文 →
PubMedNature communications2026-11-17

Developing and benchmarking one health genomic surveillance tools for influenza A virus in wastewater.

Jiang Minxi M, Wang Audrey L W ALW, Thissen James B JB, Nelson Kara L KL et al.

Influenza A viruses (IAV) remain a persistent One Health threat, and whole-genome sequencing from wastewater offers a promising surveillance tool. However, IAV is at low abundance in wastewater, making it difficult to sequence. We benchmark four targeted enrichment methods suited for multi-subtype whole-genome IAV sequencing including custom and off-the-shelf methods. Our custom HA tiled-amplicon panel is sensitive, fast, and cost-effective, making it suitable for monitoring low-abundance seasonal variants of known subtypes, although its reliance on conserved and intact primer-binding sites limits primer design to fewer subtypes. A published universal amplicon method targets all IAV subtypes but performs poorly in wastewater due to its reliance on intact genome segments. Meanwhile, probe-capture methods are resilient to RNA degradation. In real wastewater samples, our custom probe panel recovers whole-genome signals from circulating H1N1, H3N2, H5N1, including validated H5N1 2.3.4.4b reads in samples where dPCR detection is limited. However, probe-capture is generally more costly and labor-intensive than amplicon methods. Across all four sequencing methods, two wastewater matrices, and most spike-in and endogenous virus targets, ultrafiltration-based virus concentration consistently outperforms large-volume direct extraction. Together, these benchmarking comparisons and custom panels provide needed information for implementing IAV genomic sequencing in routine wastewater surveillance.

PMID 43039891
阅读全文 →
PubMedVirology journal2026-11-17

Identification of coding-region mutations associated with attenuation of an Egyptian duck hepatitis A virus type 1 isolate following serial egg passage.

Hisham Islam I, Ali Ahmed A, El-Abideen Mohamed A Zain MAZ, Adel Amany A et al.

Duck hepatitis A virus type 1 (DHAV-1) causes a highly contagious disease with high mortality in young ducklings. Although serial passage in embryonated eggs is widely used for virus adaptation and attenuation, the molecular changes associated with DHAV-1 attenuation remain poorly understood. A virulent Egyptian DHAV-1 isolate was serially passaged 84 times in embryonated chicken eggs. The parental virus (P0) and the passage-84 virus (P84) were subsequently compared for pathogenicity in Pekin ducklings, replication in embryonated chicken eggs, and whole-genome sequence analysis. The parental virus caused 100% mortality within 72 h, whereas the P84 virus caused neither clinical signs nor mortality and replicated to higher titers in embryonated chicken eggs, demonstrating complete attenuation. Whole-genome sequencing identified 11 nucleotide substitutions, including four non-synonymous mutations in the VP3, 2A, and 2C proteins. Serial passage in embryonated chicken eggs resulted in complete attenuation of DHAV-1 after 84 passages, despite the accumulation of four amino acid substitutions. These findings demonstrate that profound phenotypic attenuation can arise with minimal genomic evolution and identify candidate mutations in VP3, 2A, and particularly 2C for future reverse-genetics studies and rational live vaccine development.

PMID 43040369
阅读全文 →
PubMedBMC public health2026-11-17

Post-introduction evaluation of COVID-19 vaccine deployment in Ghana: lessons learnt to inform future new vaccine introductions and strengthen public health readiness, 2023.

Amponsa-Achiano Kwame K, Shen Angela K AK, Baiden Laryea Eunice E, Carlton Julie Garon JG et al.

On March 2nd, 2021, Ghana, the first country to receive vaccines from the COVAX facility, began its COVID-19 vaccination using a complex multi-phased approach, to reach target populations. We evaluated the vaccine deployment to document best practices challenges and lessons for future new vaccine introductions and public health emergency readiness. We conducted a mixed methods post-introduction evaluation, purposively sampling 36 facilities from 12 districts in six regions. Adapting the World Health Organization's COVID-19 Post-Introduction Evaluation tool, we conducted a cross-sectional survey using a structured questionnaire, reviewed programme records, observed practices, and interviewed purposively selected health workers, immunization managers and partners who supported vaccine deployment. We performed summary descriptive statistics on quantitative data, thematic analysis on qualitative data, and triangulated the results. As of March 2023, more than 70% of the target population (15 years and older) had received at least one dose, while more than 50% had completed the primary series. Vaccine deployment was built on the existing immunisation programme and functional coordinating bodies. Cold chain capacity was revamped with ultra-low-temperature freezers, while 33.3% of surveyed districts adjusted waste disposal systems to accommodate COVID-19 vaccine introduction. Door-to-door delivery and demand generation through varied risk communication and community engagement strategies improved vaccine access. Electronic data platforms were established, surge capacity improved, and healthcare and community workers were trained. Initial unpredictable vaccine supplies limited vaccination efforts. Changing vaccine information affected health workers' ability to engage communities with up-to-date guidance. While vaccine safety monitoring systems were in place, reporting knowledge varied among health workers, and 36% of surveyed facilities had ever documented and reported COVID-19 vaccine-related adverse events following immunisation. Challenges with electronic data systems limited timely access to and use of granular service-delivery data for decision-making. Ghana leveraged existing immunisation and emergency-response systems to make substantial progress in COVID-19 vaccine deployment. Coordination, cold chain expansion, flexible service delivery, demand generation and workforce mobilisation supported implementation. Irregular vaccine supply, data system challenges, variable adverse event reporting, waste management pressure and misinformation challenged deployment. These findings provide lessons for adult immunisation, life-course vaccination and future public health emergency readiness.

PMID 43040294
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多inactivated whole virion H1N1 vaccine